Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) Chief Medical Officer Marie-Louise Fjällskog speaks to Thomas Warner from Proactive after releasing an update on progress with the clinical stage biopharmaceutical company's phase I/II BEXMAB study.
Fjällskog gives an overview of the update, highlighting several "very nice objective responses" to Bexmarilimab treatment and saying that the data "just confirms that we have some very exciting things going on with our combination." One patient has now stayed on the treatment for 13 months, the company noted in its update.
Looking further down the line, Faron said that it expects to file the first Biologics License Application (BLA) to US Food and Drug Administration (FDA) planned by the first half of 2025.
Fjällskog also mentions that the company is currently active in recruiting more patients for its study and is opening more sites in the US and potentially in Europe to aid with the effort.
Bexmarilimab, a novel anti-Clever-1 humanised antibody, is Faron's investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function.